Unraveling a single number: Using graphics to explain Probability of Success
Markus Lange (on behalf of the PoS initiative)
March 8th
Agenda

- Introduction to the new Probability of Success framework
- Using graphics to unravel the final PoS estimate (and to explain how we got there)
PoS is one of 3 key value drivers: Expected value is maximized as a trade-off between potential value, R&D costs and PoS

Despite complexity, drug development is like a simple gamble
“Success” is more than regulatory approval: We must also meet key endpoints of the target product profile (TPP) required for market access.

Using graphics to explain Probability of Success | BBS

Expected commercial value =

Probability of Success within Phase
- Probability of Approval only
- Probability of Approval with TPP

Probability of “Success” = Regulatory approval with key endpoints of TPP required for market access

Sales forecasts assume that key endpoints of TPP are met.
We saw room for improvement in the current PoS assessment

- We need a more appropriate definition of success

- The old approach had limitations:
  - How have we done it in the past?
    1. Use “crude” benchmark probability as a starting point
    2. Subjective review and adjustment
  - PoS estimates are crude, subjective, unreliable

- We want to use any available project specific information, and want to explicitly use the data we have already collected in clinical trials.

- We want to be consistent and transparent
New PoS Framework estimates PoS to Approval with TPP at FDP by evaluating all available data in 4 incremental steps

1. **Program characteristics**
   - Predictive model based on external industry data
   - Step 1 PoS estimate

2. **Pivotal / Phase 3 risks**
   - Bayesian analysis: strength of evidence to meet TPP
   - Step 2 PoS estimate

3. **Beyond Pivotal / Ph 3 risks**
   - Adjustment algorithm calibrated by experts
   - Step 3 PoS estimate

4. **Unaccounted risks / data**
   - Subjective adjustment
   - Final PoS estimate

Exceptions only
Step 1: Use industry data to derive a tailored benchmark for the probability of approval at FDP

1. 7 program characteristics
   - Disease Area (11 categories)
   - Lifecycle Class (NME / LCM / Biosimilar)
   - Molecule Class (Protein / Small molecule / Other)
   - Drug Target (Receptor / Enzyme / Other)
   - Route of Administration (IV / IM / SQ / Other)
   - Size of Sponsor (Big Pharma / Other)
   - Breakthrough Status (Yes / No)

Predictive model based on external industry data

Step 1 PoS estimate
Use breakdown plots to assess the impact of any explanatory variables

Individual contribution of each program characteristic to the benchmark probability of success in phase 3
Step 2: Leverage clinical data to assess the chance of success in pivotal studies

- Pivotal / Phase 3 risks
- Bayesian analysis: strength of evidence to meet TPP
- Step 2 PoS estimate

• Pre-FDP data
• Design of pivotal trials
Combine external and project-specific data to assess the chance of success in pivotal trials

- Use a Bayesian approach to quantify evidence @FDP about treatment effects on 1 - 2 efficacy endpoints.
- Then simulate future pivotal trial(s)
- ... and assess the probability of meeting key efficacy success criteria.

55% chance to meet target effect
96% chance of beneficial effect

Industry benchmark (from Step 1)
Pre-FDP data
Updated evidence
Efficacy predictions
Use bar charts to see how endpoints compare and to identify bottlenecks.
Demo of application dashboard
Conclusions

- New PoS framework can give valuable new insights and a more objective view of reality...
- ... But any good statistical analyses will only be considered when presented appropriately
- Graphics are particularly essential in a many-step-process to manage expectations on the way to the final estimate
Thank you
Backup
Unraveling a single number: Using graphics to explain Probability of Success

Probability of success (PoS) is an important metric that is used by Novartis governance boards to inform decisions about which development programs to prioritize, and by teams to optimize their development strategies. To improve the accuracy, transparency and consistency of our PoS estimates, we have developed and implemented a quantitative Bayesian approach for calculating the probability of success before the planning of any pivotal trials. This approach integrates internal clinical data generated to date, together with cross-industry success rates, and the outcome is a probability.

It needs a lot to understand a single number, and visualizations are key to inform how this number came to be. In this talk, we will discuss how the use of graphics can increase the acceptance of this metric. In particular, we will demonstrate how graphics allow us to gain deeper knowledge (e.g. by identifying bottlenecks and by contextualizing information) and as a result improve decision-making.
Summary: New PoS framework can give valuable new insights and a more objective view of reality

- Fully aligned with TPP
- Simple flexible process
- Uses all available information
- Transparent
- More reliable PoS estimates enable better decisions at project & portfolio level
- Provides clear insights on impact of risk factors
- Enables effective risk management
Acknowledgements

Cross-functional team
- Steffen Ballerstedt
- Karine Baudou
- Giovanni Della Cioppa
- Lisa Hampson
- Wolfgang Kothny
- Hong Nguyen
- Pritibha Singh
- Kelvin Stott
- Michael Wittpoth

Quantitative PoS team
- Bjoern Bornkamp
- Lisa Hampson
- Bjoern Holzhauer
- Joseph Kahn
- Markus Lange
- Mustapha Larbaoui
- Wen-Lin Luo

PoS project sponsors
- Amit Agrawal
- Danny Bar Zohar

Pilot project teams
- LCZ696D GPT
- QAW039A GPT
- LNP023A GPT
- AIN457R1 GPT

Feedback & support
- Florian Bieber
- Markus Boehm
- Pascale Burtin
- Daniel Daetwyler
- Kasper Dreyer
- Eric Gibson
- Tianmeng Lyu
- Stephan Haemmerli
- Genevieve Menard

Line function experts
- Mikhail Akimov
- Renee Bergeron
- Christine Bouchet
- Caroline Boulton
- Pascale Burtin
- Stuart Byiers
- Arthur Ciociola
- Isabelle Cote
- Swati Dimitras
- Penelope Giles
- J-B. Gruenberger
- Achim Guettner
- Andreas Hartmann
- Peter Heining
- Jasper Huels
- Venkateswar Jarugula
- Patricia Kay-Mugford
- William Kluwe
- Marty Lefkowitz
- Estella Mendelson
- Mark Milton
- Betty Molloy
- Guenther Mueller-Velten
- Brian Porter
- Nikolaos Sfikas
- Rachael Steiner-Swiat
- Christine Strohmaier
- RobertFrank Wagner
- Ralph Woessner
- Mark Wuttke